Want to see COSM full AI Analyst Report?
COSM Stock Chart & Stats
$0.20
<$0.01(3.75%)
At close: 4:00 PM EDT
$0.20
<$0.01(3.75%)
Day’s Range― - ―
52-Week Range$0.16 - $1.32
Previous Close$0.2
Volume2.90M
Average Volume (3M)16.84M
Market Cap
$22.29M
Enterprise Value$25.04
Total Cash (Recent Filing)$1.84M
Total Debt (Recent Filing)$15.98M
Price to Earnings (P/E)―
Beta2.27
Next Earnings
Nov 17, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.66
Shares Outstanding100,633,770
10 Day Avg. Volume6,443,995
30 Day Avg. Volume16,844,547
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.82
Price to Sales (P/S)0.23
P/FCF Ratio-1.77
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.01
Revenue Forecast (FY)$87.30M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthTTM growth indicates the distribution and commercialization platform is expanding sales across pharmaceutical and nutraceutical channels. Sustained top-line progress could improve operating leverage over time, although conversion into profit remains unproven.
Reduced LeverageMeaningful debt reduction and lower leverage improve financial flexibility and reduce balance-sheet pressure. The remaining equity base and asset pool provide support while management works to stabilize profitability and cash generation.
Financing FlexibilityExpanded equity and preferred-share tools give Cosmos additional options to fund operations, support incentives, or pursue growth initiatives. This flexibility may help sustain the business while internal cash generation remains inadequate.
Bears Say
Persistent UnprofitabilityLow gross profitability and substantial operating and net losses show that revenue growth is not yet producing a viable profit engine. Persistent weak economics may limit reinvestment and require significant cost, pricing, or product-mix improvements.
Negative Cash GenerationOngoing operating and free-cash-flow deficits indicate that the business consumes cash despite higher revenue. Multiple years of burn increase reliance on external funding or balance-sheet actions, potentially limiting strategic flexibility.
Dilution RiskThe newly authorized securities and equity incentives can dilute existing shareholders if issued, particularly while losses and cash burn persist. Funding through equity may preserve liquidity but could reduce current holders’ ownership and economic participation.
Cosmos Holdings News
COSM FAQ
What was Cosmos Holdings’s price range in the past 12 months?
Cosmos Holdings lowest stock price was $0.16 and its highest was $1.32 in the past 12 months.
What is Cosmos Holdings’s market cap?
Cosmos Holdings’s market cap is $22.29M.
When is Cosmos Holdings’s upcoming earnings report date?
Cosmos Holdings’s upcoming earnings report date is Nov 17, 2026 which is in 83 days.
How were Cosmos Holdings’s earnings last quarter?
Cosmos Holdings released its earnings results on Aug 24, 2026. The company reported -$0.1 earnings per share for the quarter, the consensus estimate of -$0.1 by $0.
Is Cosmos Holdings overvalued?
According to Wall Street analysts Cosmos Holdings’s price is currently Overvalued.
Does Cosmos Holdings pay dividends?
Cosmos Holdings does not currently pay dividends.
What is Cosmos Holdings’s EPS estimate?
Cosmos Holdings’s EPS estimate is -0.05.
How many shares outstanding does Cosmos Holdings have?
Cosmos Holdings has 100,633,770 shares outstanding.
What happened to Cosmos Holdings’s price movement after its last earnings report?
Cosmos Holdings reported an EPS of -$0.1 in its last earnings report, expectations of -$0.1. Following the earnings report the stock price went down -6.787%.
Which hedge fund is a major shareholder of Cosmos Holdings?
Currently, no hedge funds are holding shares in COSM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cosmos Holdings
Cosmos Health Inc. functions as a vertically integrated pharmaceutical firm, providing its own line of branded and generic medicines, nutraceuticals, non-prescription drugs, healthcare and infant products, medical devices, and various other goods. These are distributed via its established channels and an e-commerce marketplace. The company actively seeks, obtains, develops, and commercializes solutions designed to improve patients' well-being and health outcomes. Supporting these operations, it maintains distribution centers in both Greece and the United Kingdom, alongside a dedicated warehousing facility. Its clientele includes wholesale pharmaceutical distributors and independent retail pharmacies. Cosmos Health Inc. was established in 2009 and has its headquarters in Chicago, Illinois.
Technical Analysis
Ownership Overview
17.36% Insiders
0.30% Mutual Funds
0.04% Other Institutional Investors
82.00% Public Companies and
Individual Investors